A new study from Italy shows that plasma therapy can significantly reduce COVID-19 moderate and patient mortality rates caused by the new coronavirus. Plasma infusions taken from recovered people can effectively improve the overall patient’s condition and reduce the risk of complications and death. Studies have also shown that antibody-based coronavirus therapy can produce the same efficacy as synthetic antibody drugs.
Infographic (from: Wikipedia / DiverDave)
Experts warn that the new coronavirus will continue for a long time, but there is no need to panic too much. In recent years, we have learned how to coexist with a variety of pathogens.
Medical advances have wiped out some of them, but some are still hard to eliminate, such as influenza and HIV. Even so, current treatments are safe and effective enough.
In the near future, even before vaccines are widely available, COVID-19 is expected to lead to reliable treatments, and we have seen a lot of evidence to support it.
For example, doctors have used multiple drugs for the treatment of COVID-19 and are developing antibody-based drugs to speed up patient recovery.
In addition, a new study by Italian doctors shows that antibody therapy is highly reliable. By extracting plasma infusions from recovered patients, the mortality rate of patients with severe illness can be effectively reduced.
In fact, doctors have been using plasma therapy in infectious diseases for more than a hundred years. The latest research cases have received good feedback from patients in many regions of the world.
It is reported that COVID-19 rehabilitation patients may carry antibodies in their blood, which can help prevent further infection of SARS-CoV-2. The stronger the immune response, the more effective the antibody may be.
Similar studies have been reported in some countries in the early days, but more data are needed to support them before they are fully rolled out.
Now, Italian doctors have presented their latest research in La Republica and Il Giorno, and will soon publish them in the medical journal.
The study involved 46 patients with varying degrees of respiratory failure, including 7 intubation patients. They are all over 18 years old, but they are not old (older people are at higher risk after all).
All were positive for the new coronavirus, CT tests showed visible signs of pneumonia on both sides, and accompanying respiratory diseases required ventilator treatment.
The study concluded that the mortality rate for patients with moderate and severe disease slowest in COVID-19 had decreased from an average of 15% to 6%.